Details for Patent: 5,886,035

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 5,886,035 protect, and when does it expire?

Patent 5,886,035 protects ZIOPTAN and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 5,886,035

Title:	Difluoroprostaglandin derivatives and their use
Abstract:	A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.
Inventor(s):	Shirasawa; Eiichi (Ikoma, JP), Kageyama; Masaaki (Ikoma, JP), Nakajima; Tadashi (Ikoma, JP), Nakano; Takashi (Yokohama, JP), Mori; Nobuaki (Yokohama, JP), Sasakura; Hideshi (Yokohama, JP), Matsumura; Yasushi (Yokohama, JP), Morizawa; Yoshitomi (Yokohama, JP)
Assignee:	Asahi Glass Company Ltd. (Tokyo, JP) Santen Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:	08/993,017
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 5,886,035
Patent Claim Types: see list of patent claims	Compound; Use;

Drugs Protected by US Patent 5,886,035

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y		REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 5,886,035

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	8-348614	Dec 26, 1996
Japan	9-074054	Mar 26, 1997
Japan	9-172477	Jun 27, 1997

International Family Members for US Patent 5,886,035

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	225770	See Plans and Pricing
Canada	2225761	See Plans and Pricing
China	1108289	See Plans and Pricing
China	1187486	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.